Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ind-Swift Laboratories's Enterprise Value is ₹15,535 Mil.
Ind-Swift Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Ind-Swift Laboratories's EV-to-FCF for today is .
The historical rank and industry rank for Ind-Swift Laboratories's EV-to-FCF or its related term are showing as below:
BOM:532305'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.47 Med: 0 Max: 0
Current: -9.47
BOM:532305's EV-to-FCF is ranked worse than 100% of 572
companies
in the Drug Manufacturers industry
Industry Median: 21.06
vs BOM:532305: -9.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ind-Swift Laboratories's PE Ratio (TTM) for today is calculated as:
Ind-Swift Laboratories's share price for today is ₹230.55.
Ind-Swift Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ind-Swift Laboratories EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ind-Swift Laboratories's EV-to-FCF falls into.
Ind-Swift Laboratories's current Enterprise Value is ₹15,535 Mil.
Ind-Swift Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Ind-Swift Laboratories (BOM:532305) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹230.55 is trading 418.8% above its estimated GF Value™ of ₹44.44.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:532305:
EV-to-FCF:
GF Value™: ₹44.44 vs. price of ₹230.55 (418.8% above fair value)
No single metric tells the full story. See the BOM:532305 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
45GF Score
Get the complete analysis for BOM:532305
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532305 has been successfully added to your 
